This was the stock's third consecutive day of gains.

Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by ...

Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and ...

Bio-Techne has a market capitalization of $12.25 billion. The Zacks Consensus Estimate for the company’s fiscal 2025 earnings indicates a 5.1% year-over-year increase on a 5.6% revenue improvement.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse ...

Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium While mutations in the ESR1 gene are exceedingly rare in cancer patients prior to treatment, the use of ...